Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastrointestinal Intolerance Clear all
Completed Phase 3 Interventional

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

NCT06060665
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Elafibranor 80mg, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Oral Fructanase Administration on Gastrointestinal Symptoms After Inulin Challenge in Healthy Adults

NCT06628869
View directory record Official record
Conditions
Digestive Health, Gastrointestinal Health, FODMAP Intolerance, Food Sensitivity
Interventions
Fructanase, Maltodextrin placebo
Dietary Supplement
Lead sponsor
BIO-CAT, Inc.
Industry
Eligibility
20 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar 10 mg, Placebo, Seladelpar 5 mg
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT03602560
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
seladelpar 5-10 mg, seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting Not applicable Interventional

Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS

NCT06609213
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
Interventions
Medical Food
Other
Lead sponsor
Andrea Charvet
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting No phase listed Observational

A Registry for the Food Allergy Community

NCT04653324
View directory record Official record
Conditions
Food Hypersensitivity, Anaphylaxis, Eosinophilic Esophagitis, Food Sensitivity, Food Intolerance, Food Allergy in Infants
Interventions
Not listed
Lead sponsor
Food Allergy Research & Education
Other
Eligibility
Not listed
Enrollment
23,000 participants
Timeline
2017 – 2027
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Perceived Lactose Intolerance

NCT01331265
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
3,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

NCT06383403
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Elafibranor, Placebo
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
20
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Active, not recruiting Phase 2 Interventional

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT05067621
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
10 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo

NCT04531033
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Lactobacillus acidophilus MPH734, Placebo
Dietary Supplement
Lead sponsor
Lemuel W. Taylor IV
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Belton, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Double Crossover Casein Type Tolerance Trial

NCT06315517
View directory record Official record
Conditions
Dairy Intolerance, Healthy Adults
Interventions
Conventional lactose-free cow's milk, Nonconventional (A2) cow's milk, Nonconventional (A2) lactose-free cow's milk
Other
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of GIMate Handheld Hydrogen Breath Monitor for Diagnosis of Lactose Malabsorption

NCT04754724
View directory record Official record
Conditions
Lactose Intolerance
Interventions
GIMate, H2 Check
Diagnostic Test
Lead sponsor
Vivante Health
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting Phase 3 Interventional

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534
View directory record Official record
Conditions
Crohn's Disease
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
12
States / cities
Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Terminated No phase listed Observational

Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants

NCT01062828
View directory record Official record
Conditions
Premature Newborn, Necrotizing Enterocolitis
Interventions
Citrulline samples
Diagnostic Test
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 16, 2026, 10:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Raw Versus Other Milk Sources on Lactose Digestion

NCT01129791
View directory record Official record
Conditions
Lactose Intolerance
Interventions
Raw Milk, Pasteurized Milk, Non-dairy milk
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 16, 2026, 10:44 AM EDT
Enrolling by invitation Phase 4 Interventional

Evaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis

NCT07583342
View directory record Official record
Conditions
Acute Pancreatitis (AP), Enhancing Enteral Nutrition Tolerance
Interventions
RELiZORB digestive enzyme (immobilized lipase) cartridge
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Bay Shore, New York • Manhasset, New York • Manhattan, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance

NCT02673749
View directory record Official record
Conditions
Lactose Intolerance
Interventions
RP-G28, Placebo
Drug · Other
Lead sponsor
Ritter Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 16, 2026, 10:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance

NCT02776098
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 16, 2026, 10:44 AM EDT
Completed Phase 2 Interventional

SAFEstart Feeding Intolerance Study Phase II

NCT00331201
View directory record Official record
Conditions
Feeding Intolerance, Abdominal Distention, Gastric Residual, Emesis and Diarrhea, Blood in Stool
Interventions
SAFEstart
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ogden, Utah
Source: ClinicalTrials.gov public record
Updated Nov 27, 2006 · Synced Sep 16, 2026, 10:44 AM EDT
Completed No phase listed Observational Results available

Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome

NCT03263819
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Oral glucose tolerance test
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
26 participants
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 7, 2024 · Synced Sep 16, 2026, 10:44 AM EDT
Withdrawn Not applicable Interventional

Diabetes Prevention and Education

NCT05769127
View directory record Official record
Conditions
Diabetes, Pre Diabetes, Fatty Liver, Body Weight Changes
Interventions
Diabetes Prevention Program (DPP), Diabetes Self-Management Training (DSMT)
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 16, 2026, 10:44 AM EDT